Original researchPreoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer
Section snippets
Materials and methods
The medical records of 142 patients treated at the University of Iowa Hospitals and Clinics for ovarian cancer between 1990 and 1996 with preoperative serum CA 125 levels were reviewed. Approval for this study was obtained from the institutional review board of the University of Iowa Hospitals and Clinics. Serum CA 125 levels were determined using a commercially available assay through Abbott Laboratories (Abbott Park, IL) for all patients. Only patients with epithelial ovarian cancer were
Results
The patient characteristics and associated preoperative CA 125 levels are listed in Table 1. The value of preoperative CA 125 ranged from 7 to 52,930 U/mL with a mean value of 2214 U/mL and a median of 582 U/mL. The mean value was greater than 75% of the observations. To evaluate the possible effect of age, patients were divided into four categories at the 25th, 50th, and 75th percentiles of distribution of age. There was no significant difference in preoperative CA 125 levels based on age (P
Discussion
Despite the proven utility of serum CA 125 levels in monitoring disease status and progression in ovarian cancer patients,1, 10 there is little information about the outcome of patients based on preoperative CA 125 levels. Previous studies have demonstrated that preoperative CA 125 levels correlate with survival in univariate analyses.20, 21 Makar et al reported that a preoperative serum CA 125 level of 150 U/mL or less was associated with better survival in univariate but not in multivariate
References (35)
- et al.
Preoperative CA 125An independent prognostic factor in patients with stage I epithelial ovarian cancer
Obstet Gynecol
(1995) - et al.
Elevated serum concentrations of CA 125 in patients with advanced endometriosis
Fertil Steril
(1986) - et al.
CA 125 in serum, peritoneal fluid, active lesions, and endometrium of patients with endometriosis
Am J Obstet Gynecol
(1988) - et al.
Placebo-controlled study on serum concentrations of CA 125 before and after treatment of endometriosis with Danazol or high-dose medroxy-progesterone acetate alone or after surgery
Fertil Steril
(1988) - et al.
CA 125 level of endometriosis
Fertil Steril
(1986) - et al.
The use of CA 125 in the diagnosis and management of endometriosis
Fertil Steril
(1986) - et al.
CA 125 kineticsA cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s
Am J Obstet Gynecol
(1996) - et al.
Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma
Am J Obstet Gynecol
(1988) - et al.
Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic massesDiscrimination of benign from malignant disease
Am J Obstet Gynecol
(1988) - et al.
The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma
Gynecol Oncol
(2000)
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancerA Gynecologic Oncology Group study
Gynecol Oncol
Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer
Gynecol Oncol
Stage IV ovarian cancerImpact of surgical debulking
Gynecol Oncol
The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma
Gynecol Oncol
Tumor antigen CA 125 as a marker of ovarian epithelial carcinoma
Gynecol Oncol
Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer
Gynecol Oncol
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer
N Engl J Med
Cited by (119)
Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer
2021, Biochimica et Biophysica Acta - Reviews on CancerCitation Excerpt :The high false-positive rate may bring a significant unnecessary psychological and therapeutic burden on women without ovarian cancer. The concentration of CA125 was not elevated to >35 U/ml in approximately 20% of patients with epithelial ovarian cancer [8]. Moreover, from the clinical data in our hospital, the level of serum CA125 had a robust relationship (P < 0.001) with neoplasm staging (Fig. 1A), which indicates that relatively low levels of CA125 are associated with earlier stages and better patient prognosis.
Prognostic significance of elevated pre-treatment serum CA-125 levels in patients with stage I ovarian sex cord-stromal tumors
2019, European Journal of Obstetrics and Gynecology and Reproductive BiologyDiagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled “Initial management of patients with epithelial ovarian cancer” developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa
2019, Gynecologie Obstetrique Fertilite et SenologieThe role of preoperative serum cancer antigen 125 in malignant ovarian germ cell tumors
2018, Taiwanese Journal of Obstetrics and GynecologyParadigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements
2024, International Journal of Molecular Sciences